Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Details
Serval ID
serval:BIB_10535
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Journal
International Journal of Cancer
ISSN
0020-7136
Publication state
Published
Issued date
1999
Volume
80
Number
2
Pages
219-230
Language
english
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; Journal Article
Abstract
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Keywords
Adult, Aged, Antigen Presentation, Antigens, Neoplasm/adverse effects, Antigens, Neoplasm/genetics, Disease Progression, Female, Genetic Code, HLA-A1 Antigen/immunology, Humans, Immunotherapy, Male, Melanoma/secondary, Melanoma/therapy, Middle Aged, Neoplasm Proteins/adverse effects, Neoplasm Proteins/genetics, Remission Induction/methods
OAI-PMH
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2007 13:00
Last modification date
20/08/2019 13:37